Project description
Harnessing microbial secondary metabolites for novel drug discovery
Microorganisms such as bacteria and fungi produce organic compounds known as secondary metabolites (SMs) with various ecological functions, including defence, competition, and communication. These metabolites are produced through biosynthetic pathways encoded in microbial genomes, but their expression remains dormant under laboratory conditions, limiting the discovery of new compounds such as antibiotics. Funded by the European Research Council, the MeDiSyn project proposes to explore untapped biosynthetic genes in soil bacteria through heterologous expression in other hosts. Researchers will optimise activation of these biosynthetic genes, paving the way towards a novel drug discovery platform.
Objective
The discoveries of microbial secondary metabolites (SM) led to an incalculable impact on human health and lifespan. A large share of the antibiotics, anticancers and immunosuppressants in use today originate from microorganisms. However, discoveries of SMs of microbial origin through traditional approaches have declined in the past decades, depriving drug pipelines from a key source of bioactive molecules. The consequences are dire, in particular in the case of antibiotics. Encouragingly, the study of the biosynthetic genes responsible for the synthesis of SMs indicates that the natural repertoire remains vastly underexplored, and new ways to access it are enabled by DNA technologies.
In particular, untapped biosynthetic genes can be interrogated by transferring them into heterologous hosts. I am developing a method for transfer which fulfils the conditions to unleash theoretically massive economies of scale. Here I propose to multiply the scalability of the current heterologous expression framework and effectively overcome the diminishing returns faced by traditional approaches.
In the first axis, I will implement a full-fledged discovery platform, optimized to systematically interrogate novel biosynthetic gene clusters identified bioinformatically from a large collection of soil bacteria. Second, the scale and parallel nature of the heterologous expression setup will be used to better understand the logic of activation of biosynthetic genes, and identify optimal ways to increase activation rates among the large reservoir of conditionally silent biosynthetic genes. Finally, the general strategy will be extended to new fungal and bacterial clades to enable interrogation of their vast potential through scalable heterologous expression.
Overall, this proposal aims at developing heterologous expression into a major way to discover microbial secondary metabolites and drug leads.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciencesbiological sciencesmicrobiologybacteriology
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Topic(s)
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
75654 Paris
France